NIH Director’s Wednesday Afternoon Lecture Series
Sounding the alarm and putting out the fire: new mechanistic insights into inflammation triggered by invasive infection
The Lieberman laboratory has been in the forefront of developing RNAi-based therapeutics and using RNAi for genome-wide screening. They were the first to demonstrate that siRNAs could protect mice from disease. They developed methods to harness RNAi to inhibit herpes and HIV transmission in animal models. They have developed strategies for cell-targeted RNAi to treat viral infection, immune disease, and cancer. They are currently investigating tumor-targeted siRNAs for immunotherapy to activate tumor expression of neoantigens and avoid autoimmune side effects of checkpoint inhibitors.
The Herbert lab investigates cellular and molecular mechanisms responsible for the initiation of Type 2 immunity against gastrointestinal helminths and enteropathogenic bacteria. We are focused upon identification of novel cytokine/receptor interactions that regulate the cross-talk between epithelial and myeloid compartments leading to pathogen clearance and tissue repair.
Our laboratory studies structural plasticity in the adult mammalian brain. We are interested in identifying the environmental, hormonal and neural stimuli that drive changes in the number, shape and size of neurons, astrocytes and microglia. The ultimate goals of our work are to determine the functional consequences of structural plasticity and to identify factors that enhance plasticity and cell survival in the adult mammalian brain.
The page was last updated on Tuesday, January 23, 2018 - 8:42am